J05: Antivirals for systemic use

ATC J05 antivirals for systemic use for modelers: models the host too.

Modified

September 21, 2026

Under construction

Table 1: Codes for antivirals.

J05	ANTIVIRALS FOR SYSTEMIC USE
J05A	DIRECT ACTING ANTIVIRALS
J05AA	Thiosemicarbazones
J05AB	Nucleosides and nucleotides excl. reverse transcriptase inhibitors
J05AC	Cyclic amines
J05AD	Phosphonic acid derivatives
J05AE	Protease inhibitors
J05AF	Nucleoside and nucleotide reverse transcriptase inhibitors
J05AG	Non-nucleoside reverse transcriptase inhibitors
J05AH	Neuraminidase inhibitors
J05AJ	Integrase inhibitors
J05AP	Antivirals for treatment of HCV infections
J05AR	Antivirals for treatment of HIV infections, combinations
J05AX	Other antivirals

Modeling notes

Models the host too. The hepatitis C model carries uninfected cells, infected cells and virions, with interferon entering as a fractional block of virion production [1]. Under a protease inhibitor, HIV load decay gave short lifespans for productively infected cells and virions [2].

References

[1]

Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-\(\alpha\) therapy. Science 1998;282:103–7. https://doi.org/10.1126/science.282.5386.103.

[2]

Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: Virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582–6. https://doi.org/10.1126/science.271.5255.1582.